Placeholder Banner

BIO Comments on FDA's Revised Draft Guidance on Submission of Quality Metrics Data

March 27, 2017

BIO submitted comments on the Food and Drug Administration’s draft guidance, Submission of Quality Metrics Data.

BIO says it’s clear FDA has seriously considered the feedback on the 2015 Draft Guidance for Industry Request for Quality Metrics. In addition, BIO remains supportive of FDA’s effort to modernize regulatory oversight of drug quality and promotion of post-approval improvements. BIO provides additional suggestions on implementation, assessment, confidentiality of data, reporting for certain covered establishments, quality metrics, and more.

 

Download Full Comments Below
2017-3-27 BIO Comments On Revised Quality Metrics FINAL
Click the link below for full comments
Discover More
The Biotechnology Innovation Organization (BIO) appreciates the opportunity to comment on the U.S. Senate Committee on Health, Education, Labor, and Pensions’ (Committee’s) Request for Information on Improving and Protecting Access to Gene Therapies…
We are writing on behalf of the Biotechnology Innovation Organization (BIO) to provide comments on the Department of Health and Human Services’ (HHS’) proposed Notice of Benefit and Payment Parameters (NBPP) for 2025.
We are writing on behalf of the Biotechnology Innovation Organization (BIO) to provide comments on the Centers for Medicare & Medicaid Services’ Draft CY 2025 Part D Redesign Program Instructions.